<?xml version="1.0" encoding="UTF-8"?>
<div class="fig" id="PMC7114316/figure_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption> Antiviral activities of the best three compounds as detected by IPMA, NSC345647 (A), NSC87511 (B), and NSC343256 (C). Lopinavir (D), an HIV-protease inhibitor, was included as a positive drug control. Three controls for each compound (FIPV infection without the compound treatment, FIPV ± Tx; no infection with compound, -FIPV/+Tx; no infection without compound, -FIPV/-Tx) are presented on the upper panel. The three-antiviral cell-based conditions; pre-viral entry, post-viral entry, and prophylaxis activities are presented as described in the text. </caption>
 <div class="graphic"/>
 <p class="label">Fig. 3</p>
</div>
